KAS
TCRT icon

Kestra Advisory Services’s Alaunos Therapeutics TCRT Stock Holding History

Kestra Advisory Services’s Portfolio TCRT Stock Details TCRT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q4 		– Sell
-86
Closed -$22K – 2340
2022
Q3 		$22K Sell
86
-42
-33% -$12.2K ﹤0.01% 2070
2022
Q2 		$24K Buy
128
+47
+58% +$4.49K ﹤0.01% 2081
2022
Q1 		$8K Hold
81
– – ﹤0.01% 1992
2021
Q4 		$13K Sell
81
-3
-4% -$659 ﹤0.01% 2000
2021
Q3 		$23K Buy
84
+3
+4% +$917 ﹤0.01% 2103
2021
Q2 		$32K Hold
81
– – ﹤0.01% 1988
2021
Q1 		$44K Sell
81
-9
-10% -$5.6K ﹤0.01% 1832
2020
Q4 		$36K Buy
90
+7
+8% +$2.78K ﹤0.01% 1829
2020
Q3 		$31K Buy
+83
New +$36.7K ﹤0.01% 1395

Other funds holding TCRT

DCM
Discovery Capital Management South Norwalk, Connecticut $1.92B AUM 218.96% 1-Year Est. Return
MP
MSD Partners New York $82.3M AUM 15.13% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
LCM
Laurion Capital Management New York $2.29B AUM 75.73% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
AC
Addison Capital Conshohocken, Pennsylvania $562M AUM 18.57% 1-Year Est. Return
SGCA
Steel Grove Capital Advisors Memphis, Tennessee $949M AUM 23.78% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Two Sigma Advisers
Two Sigma Advisers New York $51.4B AUM 31.07% 1-Year Est. Return

Kestra Advisory Services's TCRT Position: Q4 2022 in Review

Kestra Advisory Services sold out of Alaunos Therapeutics (TCRT) in Q4 2022, closing a stake of 86 shares — an estimated $22K sold.

Kestra Advisory Services first reported a position in TCRT in Q3 2020 and held it in 9 quarters. The position peaked at $44K in Q1 2021. 122 funds tracked by Wall St. Rank hold TCRT as of Q4 2022.

  • Kestra Advisory Services reported no remaining Alaunos Therapeutics position as of Q4 2022 after selling out during the quarter.
  • Kestra Advisory Services sold 86 Alaunos Therapeutics shares in Q4 2022, an estimated $22K.
  • Kestra Advisory Services first reported a position in Alaunos Therapeutics in Q3 2020 and held it in 9 quarters.
  • Kestra Advisory Services's Alaunos Therapeutics position peaked at $44K in Q1 2021.
  • 122 funds tracked by Wall St. Rank held Alaunos Therapeutics as of Q4 2022.

Based on Kestra Advisory Services's 13F filing for Q4 2022, filed 31 Jan 2023.